CWEB vs. RX, CRDL, MDP, TGOD, NINE, DB, WMD, HEXO, VIR, and ZOM
Should you be buying Charlotte's Web stock or one of its competitors? The main competitors of Charlotte's Web include BioSyent (RX), Cardiol Therapeutics (CRDL), Medexus Pharmaceuticals (MDP), Green Organic Dutchman (TGOD), Delta 9 Cannabis (NINE), Decibel Cannabis (DB), WeedMD (WMD), HEXO (HEXO), Viridium Pacific Group (VIR), and Zomedica Pharmaceuticals Corp. (ZOM.V) (ZOM). These companies are all part of the "drug manufacturers - specialty & generic" industry.
Charlotte's Web vs. Its Competitors
Charlotte's Web (TSE:CWEB) and BioSyent (CVE:RX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk and profitability.
BioSyent has a net margin of 20.60% compared to Charlotte's Web's net margin of -66.35%. BioSyent's return on equity of 20.01% beat Charlotte's Web's return on equity.
Charlotte's Web has a beta of 2.629697, meaning that its share price is 163% more volatile than the S&P 500. Comparatively, BioSyent has a beta of 0.393036, meaning that its share price is 61% less volatile than the S&P 500.
In the previous week, Charlotte's Web and Charlotte's Web both had 1 articles in the media. Charlotte's Web's average media sentiment score of 1.27 beat BioSyent's score of 1.16 indicating that Charlotte's Web is being referred to more favorably in the media.
1.4% of Charlotte's Web shares are held by institutional investors. Comparatively, 4.0% of BioSyent shares are held by institutional investors. 11.3% of Charlotte's Web shares are held by insiders. Comparatively, 33.7% of BioSyent shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
BioSyent has lower revenue, but higher earnings than Charlotte's Web. Charlotte's Web is trading at a lower price-to-earnings ratio than BioSyent, indicating that it is currently the more affordable of the two stocks.
Summary
BioSyent beats Charlotte's Web on 9 of the 12 factors compared between the two stocks.
Get Charlotte's Web News Delivered to You Automatically
Sign up to receive the latest news and ratings for CWEB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CWEB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Charlotte's Web Competitors List
Related Companies and Tools
This page (TSE:CWEB) was last updated on 10/17/2025 by MarketBeat.com Staff
